Home > Insider Trading > Filing (0001415889-24-023399)

Filing Details

Accession Number:: 0001415889-24-023399
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-09-13 18:54:09
Reporting Period:: 2024-09-11

Accepted Time:: 2024-09-13 18:54:09
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1516551	Skye Bioscience Inc.	SKYE	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1219014	M Scott Rocklage	4 Embarcadero Center, Suite 3110 San Francisco CA 94111	No	No	Yes	No
1240357	D John Diekman	4 Embarcadero Center, Suite 3110 San Francisco CA 94111	No	No	Yes	No
1386509	5Am Ventures Ii Lp	4 Embarcadero Center, Suite 3110 San Francisco CA 94111	No	No	Yes	No
1390376	5Am Co-Investors Ii Lp	4 Embarcadero Center, Suite 3110 San Francisco CA 94111	No	No	Yes	No
1555952	5Am Partners Ii, Llc	4 Embarcadero Center, Suite 3110 San Francisco CA 94111	No	No	Yes	No
1664281	Kush Parmar	4 Embarcadero Center, Suite 3110 San Francisco CA 94111	No	No	Yes	No
1844435	5Am Ventures Vii, L.p.	4 Embarcadero Center, Suite 3110 San Francisco CA 94111	No	No	Yes	No
1873545	5Am Partners Vii, Llc	4 Embarcadero Center, Suite 3110 San Francisco CA 94111	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-09-11	214,556	$6.60	8,178,964	No	4	S	Indirect	By 5AM Ventures VII, L.P.
Common Stock	Disposition	2024-09-11	36,504	$6.60	1,681,685	No	4	S	Indirect	By 5AM Ventures II, L.P.
Common Stock	Disposition	2024-09-11	1,440	$6.60	66,356	No	4	S	Indirect	By 5AM Co-Investors II, L.P.
Common Stock	Disposition	2024-09-13	11,758	$6.06	8,167,206	No	4	S	Indirect	By 5AM Ventures VII, L.P.
Common Stock	Disposition	2024-09-13	2,000	$6.06	1,679,685	No	4	S	Indirect	By 5AM Ventures II, L.P.
Common Stock	Disposition	2024-09-13	79	$6.06	66,277	No	4	S	Indirect	By 5AM Co-Investors II, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By 5AM Ventures VII, L.P.
No	4	S	Indirect	By 5AM Ventures II, L.P.
No	4	S	Indirect	By 5AM Co-Investors II, L.P.
No	4	S	Indirect	By 5AM Ventures VII, L.P.
No	4	S	Indirect	By 5AM Ventures II, L.P.
No	4	S	Indirect	By 5AM Co-Investors II, L.P.

Footnotes

The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.05 to $6.11 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.